Índice preditor de reserva ovariana (ORPI) para controle de estimulação ovariana individualizado
Nenhuma Miniatura disponível
Data
2013-05-03
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Tipo
Artigo
Direito de acesso
Acesso restrito
Resumo
Objective: to expand the evaluation of a new ovarian response prediction index (ORPI), which was based on the AMH, AFC and age, and to verify its reability as a predictor of ovarian response to stimulation in assisted reproductive technology (ART) cycles. Methods: A total of 129 patients enrolled in the ICSI programme were included. The ORPI values were calculated by multiplying the AMH level (ng/ml) by the number of antral follicles (2-9 mm), and the result was divided by the age (years) of the patient (ORPI=(AMH × AFC)/Patient age). Results: Spearman's test revealed significant correlations (P<0.0001) between the ORPI and the number of oocytes collected and the number of follicles. Logistic regression revealed that ORPI values were significantly associated with the likelihood of collecting ≥4 oocytes (OR=45.56), ≥4 MII oocytes (OR=6.01) and ≥15 oocytes (OR=6.15; P<0.0001). Based on the ROC curves, the ORPI accurately predicted a low ovarian response (<4 oocytes retrieved; area under the curve (AUC):0.91), collection of ≥4 MII oocytes (AUC:0.85) and an excessive ovarian response (≥15 oocytes retrieved; AUC:0.89). Conclusions: The ORPI exhibited an excellent ability to predict a low ovarian response and a good ability to predict a collection of ≥ 4 MII oocytes, an excessive ovarian response. The ORPI might be used to improve the cost-benefit ratio of ovarian stimulation regimens by guiding the selection of medications and by modulating the doses and regimens according to the actual needs of the patients. © Todos os direitos reservados a SBRA - Sociedade Brasileira de Reprodução Assistida.
Descrição
Palavras-chave
Age , Anti-Mullerian hormone , Antral follicles , Individualized controlled ovarian stimulation , Ovarian response prediction index , cetrorelix , chorionic gonadotropin , leuprorelin , luteinizing hormone , Muellerian inhibiting factor , recombinant follitropin , adult , age , cost benefit analysis , drug dose increase , female , human , major clinical study , named inventories, questionnaires and rating scales , oocyte , ovarian response prediction index , ovary follicle , ovary function , transvaginal echography
Idioma
Inglês
Como citar
Jornal Brasileiro de Reproducao Assistida, v. 17, n. 2, p. 77-83, 2013.